



Dengue**Motion**

Sanofi Pasteur:
A partner in eradicating vaccine preventable diseases and improving access to vaccines

Vaccines: the single most effective medical intervention

■ Vaccines save lives

Millions of cases of disease prevented

- Smallpox has been eradicated
 - Before eradication in 1980, smallpox threatened 60% of the world's population and killed 1 out of 4 people infected ⁽¹⁾
- Polio infections have fallen globally by 99% since 1988 ⁽²⁾
 - An estimated 5 million people have escaped paralysis
- Measles mortality has decreased by 74% worldwide between 2000 and 2007 ⁽³⁾

(1) WHO – Factsheet n° 288 – March 2005

(2) Global Polio Eradication Initiative (GPEI). Global Situation - Jan 2009

(3) WHO – 10 Facts on Immunization – Oct 2009
<http://www.who.int/features/factfiles/immunization/en/index.html>

■ Vaccines save money

Vaccination is undoubtedly one of the most cost-effective public health care investments available

- In the United States, cost-benefit analysis indicate that every dollar invested in a vaccine dose saves US \$2 to US \$27 in health-care expenses ⁽¹⁾
- A study of 11 western European countries reported that the cost of measles treatment was €209-480 per case, while the cost of measles vaccination and control was €0.17-0.97 per person⁽²⁾

(1) WHO. Immunization against diseases of public health importance – fact sheet n° 288. March 2005

(2) Carabin 2003 - WHO European Region –Seven Key Reasons Why immunization must remain a priority in the WHO European Region
http://www.euro.who.int/__data/assets/pdf_file/0017/84302/Seven_Key_Reasons.pdf



VISION

SANOFI PASTEUR PHILIPPINES will further strengthen its leadership in vaccines by putting immunization at the forefront of all healthcare discussions. We will continue to provide superior and innovative products for the prevention of disease, looking for ways to improve patient access to its existing vaccines no matter where they live. Along with our partners in the immunization community, we will carry this out with passion knowing that we make a difference in the lives of Filipinos.

MISSION

Build a NATION where no one suffers or dies from vaccines-preventable disease.

A young child with a joyful expression is clapping their hands in a field of tall grass under a bright sky. The child is wearing a green and white plaid shirt and olive green pants.

CREATING
VACCINES.
PROTECTING
LIFE

The Broadest Range of Vaccines Worldwide

Vaccines against 20 diseases

Viral diseases



Yellow fever



Mumps



Poliomyelitis



Measles



Rubella



Influenza



Hepatitis A



Hepatitis B



Rabies



Chickenpox



Japanese encephalitis

Bacterial diseases



Pertussis



Diphtheria



Haemophilus influenzae type b infections



Meningococcal meningitis



Pneumococcal infections



Tetanus



Tuberculosis



Typhoid fever



Cholera



and against one eradicated disease



Smallpox (*)

(*) This vaccine is produced in response to the threat of bioterrorism using strains of the smallpox virus.

Dengue is a major public health and economic burden in the Philippines



\$309M for hospitalized cases
\$36M for ambulatory cases

Direct medical \$345M

\$218M in the private sector
\$127M in the public sector

842,867 cases annually between 2008 and 2012 considering an adjustment factor of 7.2


References:

1. Department of Health, FSHIS, Morbidity 1991-2013
2. Dengue Laboratory-based Surveillance Update
3. Edillo F., et al, Cost Burden of Dengue in the Philippines

SANOFI PASTEUR HAS A UNIQUE, LONG-STANDING COMMITMENT TO DEVELOPING A DENGUE VACCINE



Dengue**Motion**



SPGLB.DENG.14.12.0102
sanofi pasteur, data on file, 2013, Dengue Factsheet.

IN 2014, RESULTS FROM TWO PHASE III EFFICACY STUDIES OF THE CANDIDATE DENGUE VACCINE WERE PUBLISHED



Dengue**Motion**

The NEW ENGLAND JOURNAL of MEDICINE

THE LANCET

Articles



The NEW ENGLAND JOURNAL of MEDICINE

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

Luis Villar, M.D., Gustavo Horacio Dayan, M.D., José Luis Arredondo-García, M.D., Doris Maribel Rivera, M.D., Rivaldo Cunha, M.D., Carmen Deseda, M.D., Humberto Reynales, M.D., Maria Selma Costa, M.D., Javier Osvaldo Morales-Ramírez, M.D., Gabriel Carrasquilla, M.D., Luis Carlos Rey, M.D., Reynaldo Dietze, M.D., Kleber Luz, M.D., Enrique Rivas, M.D., Maria Consuelo Miranda Montoya, M.D., Margarita Cortés Supelano, M.D., Betzana Zambrano, M.D., Edith Langevin, M.Sc., Mark Boaz, Ph.D., Nadia Tornieperth, M.D., Melanie Saville, M.B., B.S., and Fernando Noriega, M.D., for the CYD15 Study Group*



Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

*Maria Rosario Capeding, Ngoc Huu Tran, Sri Rezeki S Hadinegoro, Hussain Imam HJ Muhammad Ismail, Tawee Chotpitayasunondh, Mary Noreen Chua, Chan Quang Luong, Kusnandi Rusmil, Dewa Nyoman Wirawan, Revathy Nallusamy, Punnee Pitisuttithum, Usa Thisyakorn, In-Kyu Yoon, Diane van der Vliet, Edith Langevin, Thelma Laot, Yanee Hutagalung, Carina Frago, Mark Boaz, T Anh Wartel, Nadia G Tornieperth, Melanie Saville, Alain Bouckennooghe, and the CYD14 Study Group**

<http://linkinghub.elsevier.com/retrieve/pii/S0140673614610606>

<http://www.nejm.org/doi/full/10.1056/NEJMoa1411037>

- **Vaccination is the single most effective medical intervention**
 - Vaccines saves lives
 - Vaccines save money
 - But there are challenges remain particularly there is poor access to life saving vaccinations...

- **Sanofi Pasteur is a global leader in the fight to eradicate infectious diseases and improve global health.**

- **Sanofi Pasteur will be launching the a Dengue Vaccine, which has been shown in clinical trials to be effective and safe, in the near future. This vaccine will provide the DOH and LGU an additional tool in the fight against Dengue**

- **Sanofi Pasteur is committed in supporting the government's drive to fight infectious disease through advocacy, disease surveillance, and improving access to vaccination.**





Dengue**Motion**

Thank you for listening

Contact Persons:

Dr. Dennis Quiambao , Vaccine Policy and Advocacy Director

Dennis.Quiambao@sanofipasteur.com / 0998 959 3241

Dr. Joseph Anthony Lachica, Vaccine Policy and Advocacy Manager

Joseph.Lachica@sanofipasteur.com / 0998 962 6078